{"id":112717,"date":"2022-07-14T09:27:49","date_gmt":"2022-07-14T09:27:49","guid":{"rendered":"https:\/\/euretina.org\/?post_type=resource&p=112717"},"modified":"2022-08-15T22:41:03","modified_gmt":"2022-08-15T22:41:03","slug":"free-paper-session-ird-i","status":"publish","type":"resource","link":"https:\/\/euretina.org\/resource\/free-paper-session-ird-i\/","title":{"rendered":"Free Paper Session 1: IRD I"},"content":{"rendered":"\n
Time & Date:<\/strong> 1 September, 14:45 – 15:45 CEST Speakers:<\/strong><\/p>\n\t\t\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t Presentations:<\/strong><\/p>\n\t\t\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t Speakers & Presentations:<\/strong><\/p>\n\t\t\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n I. Audo FRANCE<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 14:45 <\/em>Welcome<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n N. Paudel IRELAND<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 14:47 <\/em>Genetic testing experiences of people living with inherited retinal diseases (IRDs) \u2013 results of a global survey<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n I. Audo FRANCE<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 14:53<\/em> RLIGHT – Observational study on the use of voretigene neparvovec (VN) in patients with inherited retinal dystrophy (IRD) at CHNO des Quinze-Vingts: a 1-year follow-up safety and efficacy results<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n D. Fischer UK<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 14:59<\/em> Real-world safety and effectiveness of voretigene neparvovec: Year 2 interim results from the PERCEIVE study<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n V. Gonzalez USA<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 15:05<\/em> Development of Novel Endpoints for the Study of Multi-Characteristic Opsin Enabled Vision Restoration in Patients with Advanced Retinitis Pigmentosa; Double-masked, Randomized, sham-controlled, Multicenter Phase 2b study<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n J. Wawrzynski UK<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 15:11 <\/em>Intravitreal Cerliponase alfa for the treatment of Neuronal Ceroid Lipofuscinosis type 2 (CLN2) related retinal dystrophy: A first in man report of ocular enzyme replacement.<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n S.N Geada Batista PORTUGAL<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 15:17 <\/em>Expanding the mutational spectrum of CNGB1-associated RP-olfactory dysfunction syndrome<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n L. Mautone GERMANY<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 15:23<\/em> Diurnal changes of macular anatomy and sensitivity in X-linked juvenile retinoschisis<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n H. Baran \u00d6zdemir TURKEY<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 15:29<\/em> Congenital X-Linked Retinoschisis: Surgical Needs and Outcomes in Long Term. A Retrospective Multicenter International Study<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n M. Mateos SPAIN<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 15:35<\/em> Hair cortisol level as a molecular biomarker in retinitis pigmentosa patients<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n
Chairpersons:<\/strong> D. Fischer UK <\/em>& I. Audo FRANCE<\/em><\/p>\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n